ArriVent BioPharma (NASDAQ:AVBP) Stock Rating Upgraded by Wall Street Zen

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other equities analysts also recently weighed in on AVBP. Guggenheim raised their price objective on ArriVent BioPharma from $18.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Jefferies Financial Group set a $18.00 target price on ArriVent BioPharma in a research report on Tuesday, October 6th. BTIG Research reissued a “buy” rating and issued a $29.00 target price on shares of ArriVent BioPharma in a report on Friday, October 16th. Oppenheimer restated an “outperform” rating and issued a $25.00 price target on shares of ArriVent BioPharma in a research report on Monday, October 26th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a research report on Thursday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.89.

Read Our Latest Report on AVBP

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $13.01 on Friday. ArriVent BioPharma has a 12-month low of $11.36 and a 12-month high of $35.83. The stock has a market cap of $672.88 million, a PE ratio of -3.61 and a beta of 1.66. The company has a 50-day moving average of $21.36 and a two-hundred day moving average of $26.40.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $5.00 million for the quarter, compared to analyst estimates of $0.80 million. On average, sell-side analysts forecast that ArriVent BioPharma will post -3.81 EPS for the current fiscal year.

Institutional Trading of ArriVent BioPharma

Several large investors have recently modified their holdings of the business. Entropy Technologies LP acquired a new position in shares of ArriVent BioPharma during the 3rd quarter worth approximately $478,000. Jump Financial LLC lifted its stake in ArriVent BioPharma by 173.5% in the 3rd quarter. Jump Financial LLC now owns 81,067 shares of the company’s stock valued at $2,455,000 after buying an additional 51,423 shares in the last quarter. Alps Advisors Inc. lifted its stake in ArriVent BioPharma by 38.7% in the 3rd quarter. Alps Advisors Inc. now owns 65,315 shares of the company’s stock valued at $1,978,000 after buying an additional 18,241 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in ArriVent BioPharma during the 3rd quarter valued at $76,000. Finally, Profund Advisors LLC grew its holdings in ArriVent BioPharma by 12.8% during the 3rd quarter. Profund Advisors LLC now owns 14,257 shares of the company’s stock valued at $432,000 after buying an additional 1,614 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors and hedge funds.

About ArriVent BioPharma

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

Further Reading

Analyst Recommendations for ArriVent BioPharma (NASDAQ:AVBP)

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.